Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid Tumors
Public ClinicalTrials.gov record NCT04774952. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1/1b, Open-Label, Multicenter, Dose-Escalation Study of RMC 5552 Monotherapy in Adult Subjects With Relapsed/Refractory Solid Tumors
Study identification
- NCT ID
- NCT04774952
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Revolution Medicines, Inc.
- Industry
- Enrollment
- 58 participants
Conditions and interventions
Conditions
Interventions
- RMC-5552 Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 6, 2021
- Primary completion
- May 5, 2024
- Completion
- Jun 27, 2024
- Last update posted
- Apr 14, 2025
2021 – 2024
United States locations
- U.S. sites
- 8
- U.S. states
- 6
- U.S. cities
- 8
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| UC Irvine - Chao Family Comprehensive Cancer Center | Irvine | California | 92868 | — |
| UC Davis Comprehensive Cancer Center | Sacramento | California | 95817 | — |
| UC San Francisco - Helen Diller Family Comprehensive Cancer Center | San Francisco | California | 94115 | — |
| Moffitt Cancer Center | Tampa | Florida | 33612 | — |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10021 | — |
| University of Oklahoma - Stephenson Cancer Center | Oklahoma City | Oklahoma | 73104 | — |
| Sarah Cannon Research Institute - Tennessee Oncology, PLLC | Nashville | Tennessee | 37203 | — |
| Dell Seton Medical Center at University of Texas | Austin | Texas | 78712 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04774952, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 14, 2025 · Synced May 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04774952 live on ClinicalTrials.gov.